Extending the duration of cytomegalovirus prophylaxis to 6 months in virus-seronegative organ recipients who receive transplants from seropositive donors decreases the risk of cytomegalovirus disease. But is prophylaxis extension the best approach to preventing late-onset cytomegalovirus disease?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Luan, F. L. et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J. Am. Soc. Nephrol. 20, 2449–2458 (2009).
Paya, C. et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4, 611–620 (2004).
Humar, A. et al. The IMPACT Study: Valganciclovir prophylaxis for until 200 days post-transplant in high risk kidney recipients substantially reduces the incidence of CMV disease [abstract]. Presented at the American Transplant Congress 2009.
Boivin, G. et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. 189, 1615–1618 (2004).
Humar, A. et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am. J. Transplant. 5, 1065–1070 (2005).
Emery, V. C. et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355, 2032–2036 (2000).
Kumar, D. et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk organ transplant recipients. Am. J. Transplant. 9, 1214–1222 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. Kumar declares association with the following companies: Roche and Cellestis, as recipient of grant/research support. A. Humar declares association with the following companies: Roche, as recipient of speakers bureau (honoraria) and grant/research support, Cellestis, as recipient of grant/research support, and ViroPharma, as recipient of speakers bureau (honoraria).
Rights and permissions
About this article
Cite this article
Kumar, D., Humar, A. Cytomegalovirus prophylaxis: how long is enough?. Nat Rev Nephrol 6, 13–14 (2010). https://doi.org/10.1038/nrneph.2009.207
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.207
